HER2 測試市場：市場規模（按細分市場）、份額、監管、報銷、預測（~2033 年）

乳癌是女性最常見的癌症，也是目前全球女性癌症相關死亡的主要原因。 2018年，報告了約1800萬新發乳癌病例，新診斷病例約210萬例，幾乎佔女性癌症病例的四分之一。

人類表皮生長因子受體 2 (HER2) 是一種跨膜酪胺酸激□受體，屬於表皮生長因子受體 (EGFR) 家族。 此蛋白由位於 17 號染色體長臂 (17q12-21.32) 的 HER2 (ERBB2) 基因編碼。 HER2 的不當活化與多種惡性腫瘤的發生有關，包括乳癌、胃癌、卵巢癌、大腸癌、胰臟癌和子宮內膜癌。 準確評估 HER2 狀態對於確定最能從抗 HER2 標靶治療中受益的患者至關重要。

在乳癌中，18% 至 20% 的患者出現 HER2 基因擴增。 另一方面，胃癌患者的 HER2 陽性率根據組織學亞型和部位的不同從 10% 到 30% 不等。

HER2檢測模型包括HER2免疫組織化學（IHC）檢測、HER2原位雜交（ISH）檢測和HER2比較基因組雜交（aCGH）檢測。

本報告深入探討了全球 HER2 檢測市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響以及區域和國家趨勢。Masu。

目錄

目前HER2的市場測試及競爭狀況

• 對主要產業趨勢的見解
• 2015 年至 2033 年 HER2 測試按細分市場劃分的市場總收入和市場前景
• 按細分市場劃分的手術總數、單位數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• HER2檢測市場的SWOT分析
• HER2 檢測市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

HER2 Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on HER2 Tests market for the year 2020 and beyond. Breast cancer is the most frequent cancer in women and is now the leading cause of female cancer-related deaths worldwide. Approximately 18 million new breast cancer cases were reported in 2018, with approximately 2.1 million newly diagnosed cases, accounting for almost 1 in 4 cancer cases among women.

Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor belonging to the family of epidermal growth factor receptors (EGFRs). The protein is encoded by the HER2 (ERBB2) gene, which is located on the long arm of chromosome 17 (17q12-21.32). The inappropriate activation of HER2 is associated with the development of several malignancies, including breast, gastric, ovarian, colorectal, pancreatic, and endometrial cancers. An accurate evaluation of HER2 status is crucial for identification of patients who would most likely benefit from targeted anti-HER2 therapies.

In breast cancer, HER2 gene amplification, occurs in 18% to 20% of patients. On the other hand, the reported HER2 positivity in patients with gastric cancer ranges widely from 10% to 30% depending on the histologic subtype and location.

HER2 Tests model includes HER2 Immunohistochemistry (IHC) Tests, HER2 In Situ Hybridization (ISH) Tests and HER2 Comparative Genomic Hybridization (aCGH) Tests

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed HER2 Tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total HER2 tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for HER2 Tests market.
• Competitive dynamics insights and trends provided for HER2 Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Agilent Technologies Inc, Amoy Diagnostics Co Ltd, Biocare Medical LLC, Merck KGaA,F. Hoffmann-La Roche Ltd, Illumina Inc, Danaher Corp, medac GmbH, New England Biolabs Inc, Qiagen NV, Sysmex Corp, Thermo Fisher Scientific Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the HER2 Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on HER2 Tests market.
• Develop and design you're in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving HER2 Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HER2 Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific HER2 Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable